KEI Briefing Note 2016:2: 2015-2016 Pharmaceutical Transparency Legislation
The attached briefing note analyzes transparency legislation that has been proposed in 14 states in 2015 and 2016. The bills would require various degrees of transparency for research and development (R&D) and marketing costs, as well as for drug prices and price changes.
Continue Reading